New precision medicine guidelines - personalized treatment plans

cp418

http://www.sciencedaily.com/releases/2016/01/16011...

New precision medicine guidelines aimed at improving personalized cancer treatment plans

A committee of national experts has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes.

BarredOwl

Thanks cp418:

Here is a link to the .pdf of the featured article.

http://onlinelibrary.wiley.com/doi/10.3322/caac.21...

The American Joint Committee on Cancer (AJCC) promulgates the "TNM" staging criteria for solid tumors (e.g., breast cancer). The current edition is the 7th Edition of the AJCC Cancer Staging Manual. For other solid tumor types, additional factors have been added to refine staging criteria. There is an effort underway to do more of this. The 8th Edition of the AJCC staging system is expected to be published in 2016:

"The AJCC has increasingly recognized the growing need for more accurate and probabilistic individualized outcome prediction for precision medicine that would incorporate additional anatomic and nonanatomic prognostic factors beyond TNM. Toward this, since 2002 (6th edition), it has judiciously included, albeit very infrequently, nonanatomic factors that modified stage groupings. In the current 7th edition, the trend toward expansion of relevant markers to make clear treatment decisions included, for example, adding mitotic rate in gastrointestinal (GI) stromal tumors and melanomas, and prostate-specific antigen (PSA) level and Gleason score in stage grouping classification of prostate cancer. . .

. . .To maintain the primary goal of the AJCC staging as the definitive, comprehensive, evidence-based, and clinically relevant classification, the editorial board of the 8th edition reaffirmed the anatomic stage and extent of disease basis of classification but with a deliberate effort to increasingly incorporate molecular biomarkers for accurate risk stratification that will help retain its fundamental role in defining a patient's prognosis and appropriate disease management but will be enhanced by this new vision to guide precision therapy. The 8th edition, to be published in 2016, was expanded to include the Personalized Medicine Core (PMC) and the Evidence-Based Medicine and Statistics Core (EMBS)."

BarredOwl